Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US9512211B2 · kind B2 · utility
0Cited by
22References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2014 |
| Grant date | Dec 6, 2016 |
| Priority date | — |
| Expiry date | Jun 23, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.